NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free ANIX Stock Alerts $3.19 +0.21 (+7.05%) (As of 01:20 PM ET) Add Compare Share Share Today's Range$3.13▼$3.3250-Day Range$2.98▼$4.0552-Week Range$2.75▼$5.13Volume170,611 shsAverage Volume142,017 shsMarket Capitalization$101.76 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Anixa Biosciences alerts: Email Address Anixa Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside281.0% Upside$12.00 Price TargetShort InterestHealthy1.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$182,130 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.44) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector551st out of 908 stocksPharmaceutical Preparations Industry250th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingAnixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.82% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Anixa Biosciences has recently decreased by 3.96%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANIX. Previous Next 0.7 News and Social Media Coverage News SentimentAnixa Biosciences has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Anixa Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $182,130.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.60% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.13% of the stock of Anixa Biosciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.44) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -9.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -9.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Anixa Biosciences Stock (NASDAQ:ANIX)Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Read More ANIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIX Stock News HeadlinesApril 11, 2024 | insidertrades.comLewis H. Titterton, Jr. Acquires 15,009 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockApril 21, 2024 | americanbankingnews.comMacroGenics (NASDAQ:MGNX) versus Anixa Biosciences (NASDAQ:ANIX) Critical ComparisonApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 18, 2024 | finance.yahoo.comAnixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory BoardMarch 16, 2024 | finance.yahoo.comANIX Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comANIX Apr 2024 2.500 putMarch 14, 2024 | prnewswire.comAnixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested PartiesMarch 12, 2024 | benzinga.comRecap: Anixa Biosciences Q1 EarningsApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 11, 2024 | prnewswire.comAnixa Biosciences Announces Presentation at 24th Annual World Vaccine CongressFebruary 22, 2024 | benzinga.comAnixa Biosciences Stock (NASDAQ:ANIX) Insider TradesFebruary 21, 2024 | investing.comAnixa Biosciences Inc (ANIX)February 17, 2024 | finance.yahoo.comWe Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business GrowthFebruary 17, 2024 | finance.yahoo.comANIX Feb 2024 5.000 callFebruary 13, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Anixa Biosciences (ANIX) and InMode (INMD)February 12, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical TrialFebruary 12, 2024 | finance.yahoo.comAnixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical TrialFebruary 6, 2024 | finance.yahoo.com3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023January 30, 2024 | ca.finance.yahoo.comDogs Can Suffer from Depression — Here Are Signs to Look Out for and How to Diagnosis ThemJanuary 30, 2024 | msn.comHere’s Why You Get a Runny Nose When You’re EatingJanuary 30, 2024 | ca.news.yahoo.comVisible wants to track your illness, more than your fitnessJanuary 30, 2024 | ca.finance.yahoo.comRecalled cinnamon applesauce pouches were never tested for lead, FDA reportsJanuary 30, 2024 | ca.style.yahoo.comIf You Suffer From Intense PMS, This Condition Could Be The CauseJanuary 30, 2024 | ca.style.yahoo.comKing Charles smiles as he leaves hospital following prostate procedureJanuary 30, 2024 | msn.comKristen Dahlgren: Why I’m leaving NBC to launch a nonprofit to make breast cancer vaccines a realityJanuary 29, 2024 | finance.yahoo.comAnixa Biosciences Announces Participation in 2024 NeauxCancer Oncology ConferenceJanuary 23, 2024 | msn.comAnixa ovarian cancer vaccine tech gets Japanese patentSee More Headlines Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/26/2024Next Earnings (Estimated)6/12/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANIX CUSIPN/A CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees4Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+302.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,810,000.00 Net MarginsN/A Pretax Margin-5,174.29% Return on Equity-44.09% Return on Assets-40.90% Debt Debt-to-Equity RatioN/A Current Ratio15.19 Quick Ratio15.19 Sales & Book Value Annual Sales$210,000.00 Price / Sales452.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book3.97Miscellaneous Outstanding Shares31,900,000Free Float24,691,000Market Cap$95.06 million OptionableOptionable Beta0.84 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Amit Kumar Ph.D. (Age 60)CEO, Chairman & Co-Chair of CBAB Comp: $1.29MMr. Michael J. Catelani CPA (Age 57)MBA, President, COO, CFO & Corporate Secretary Comp: $788.83kMr. John Roop (Age 74)Senior Vice President of Engineering Comp: $275kDr. Pamela D. Garzone Ph.D. (Age 69)Chief Development Officer & Chair Breast Cancer Clinical Advisory Board Key CompetitorsVaccitechNASDAQ:VACCIO BiotechNASDAQ:IOBTCellectar BiosciencesNASDAQ:CLRBOramed PharmaceuticalsNASDAQ:ORMPBarinthus BiotherapeuticsNASDAQ:BRNSView All CompetitorsInsiders & InstitutionsSimplicity Wealth LLCBought 13,969 shares on 4/24/2024Ownership: 0.044%Lewis H Titterton JrBought 15,009 shares on 4/9/2024Total: $49,229.52 ($3.28/share)Amit KumarBought 30,000 shares on 3/15/2024Total: $96,600.00 ($3.22/share)Arnold M BaskiesBought 10,000 shares on 3/15/2024Total: $36,300.00 ($3.63/share)Amit KumarSold 11,800 sharesTotal: $42,126.00 ($3.57/share)View All Insider TransactionsView All Institutional Transactions ANIX Stock Analysis - Frequently Asked Questions Should I buy or sell Anixa Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIX shares. View ANIX analyst ratings or view top-rated stocks. What is Anixa Biosciences' stock price target for 2024? 1 brokers have issued 12-month price targets for Anixa Biosciences' stock. Their ANIX share price targets range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 281.0% from the stock's current price. View analysts price targets for ANIX or view top-rated stocks among Wall Street analysts. How have ANIX shares performed in 2024? Anixa Biosciences' stock was trading at $3.88 at the beginning of 2024. Since then, ANIX shares have decreased by 18.8% and is now trading at $3.15. View the best growth stocks for 2024 here. When is Anixa Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our ANIX earnings forecast. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences, Inc. (NASDAQ:ANIX) released its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anixa Biosciences investors own include Cronos Group (CRON), Innovative Industrial Properties (IIPR), Roku (ROKU), Ally Financial (ALLY), Albireo Pharma (ALBO), Air Lease (AL), Akoustis Technologies (AKTS), Akero Therapeutics (AKRO), Aimmune Therapeutics (AIMT) and Advanced Emissions Solutions (ADES). Who are Anixa Biosciences' major shareholders? Anixa Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Simplicity Wealth LLC (0.04%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Lewis H Titterton Jr and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANIX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
